Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials

Trial Profile

Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Riferminogene pecaplasmide (Primary)
  • Indications Peripheral arterial disorders; Peripheral arterial occlusive disorders
  • Focus Adverse reactions
  • Acronyms TALISMAN S
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top